Dr. Rezvani’s research focuses on developing novel NK cell therapies for multiple myeloma (MM) by engineering NK cells to enhance persistence, trafficking, and tumor clearance. She is leading efforts to advance CD70-targeted CAR NK cells for t(14;4) MM and a first-in-class NY-ESO TCR NK cell approach to improve tumor recognition and cytotoxicity.
A key aspect of her work involves single-cell analyses post-adoptive transfer to understand homing, response, and resistance, guiding next-generation NK cell therapies for MM. Her team has initiated multiple clinical trials of CAR NK cells, including the first-in-human study of off-the-shelf CAR NK cells for relapsed/refractory lymphoid malignancies, which showed remarkable responses in patients who had exhausted other options.
Katy Rezvani, M.D. Ph.D.
Vice president and Melvyn N. Klein Family Endowed Director
Institute for Cell Therapy Discovery & Innovation
Sally Cooper Murray Chair in Cancer Research
Professor of Medicine
Medical Director GMP Laboratories
